Myriad Genetics Q3 Adj EPS $(0.03) Beats $(0.08) Estimate, Sales $191.90M Beat $179.25M Estimate
Portfolio Pulse from bharat@benzinga.com
Myriad Genetics reported Q3 adjusted EPS of $(0.03), beating the estimate of $(0.08) by 62.5%. The company also reported quarterly sales of $191.90M, surpassing the estimate of $179.25M by 7.06%. This represents a 84.21% increase in EPS and a 22.70% increase in sales compared to the same period last year.
November 06, 2023 | 9:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Myriad Genetics reported better than expected Q3 results, with both EPS and sales beating estimates. This could potentially lead to a positive market reaction.
Myriad Genetics reported strong Q3 results, with both EPS and sales beating analyst estimates. This outperformance could lead to increased investor confidence and a potential rise in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100